Copertina

Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Denis M. Schewe, Fotini Vogiatzi, Ira A. Münnich, Tobias Zeller, Roland Windisch, Christian Wichmann, Kristina Müller, Hilal Bhat, Elisa Felix, Dimitrios Mougiakakos, Heiko Bruns, Lennart Lenk, Thomas Valerius, Andreas Humpe, Matthias Peipp, Christian Kellner
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Combination of targeted pharmacotherapy and immunotherapy with anti‐CD19 CAR NK cells in acute lymphoblastic leukemia
di: Hanna Kirchhoff, et al.
Pubblicazione: (2025)

The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia
di: Ben Watts, et al.
Pubblicazione: (2025)

Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia
di: Sanaa Khan, et al.
Pubblicazione: (2024)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
di: Martijn W. C. Verbeek, et al.
Pubblicazione: (2025)

Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma
di: Ramin Raoof, et al.
Pubblicazione: (2026)

The rearrangement partner and the presence of MYC mutations determine the outcome of patients with MYC and BCL6 rearrangements
di: Anna Stengel, et al.
Pubblicazione: (2026)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
di: Sophia Stock, et al.
Pubblicazione: (2025)

Hyperdiploid acute lymphoblastic leukemia in children with LZTR1 germline variants
di: Lisa Zipper, et al.
Pubblicazione: (2024)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
di: Rebeqa Gunnarsson, et al.
Pubblicazione: (2025)

Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
di: Inna Y. Gong, et al.
Pubblicazione: (2024)

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD‐1 blockade
di: Thomas M. Kuczmarski, et al.
Pubblicazione: (2025)

T‐cell lymphoblastic lymphoma in constitutional mismatch repair deficiency (CMMRD): Exploring treatment opportunities
di: Emma Kroeze, et al.
Pubblicazione: (2024)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
di: Wassilis S. C. Bruins, et al.
Pubblicazione: (2024)

Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results
di: Josep‐Maria Ribera, et al.
Pubblicazione: (2024)

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
di: Anna Pia Enblad, et al.
Pubblicazione: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
di: Mwanasha H. Merrill, et al.
Pubblicazione: (2025)

Circulating tumor‐associated and neoantigen‐specific endogenous T cells in children treated for B‐acute lymphoblastic leukemia
di: Eliane Huwiler, et al.
Pubblicazione: (2025)

Pharmacological inhibition of sclerostin protects bone from B‐cell acute lymphoblastic leukemia‐mediated destruction
di: Vincent Kuek, et al.
Pubblicazione: (2026)

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T‐cell lymphoblastic leukemia
di: André Almeida, et al.
Pubblicazione: (2024)

TLX1 translocation variants and enhancer hijacking influence clinical outcome in T‐cell acute lymphoblastic leukemia
di: Estelle Balducci, et al.
Pubblicazione: (2025)

Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells
di: Gloria Iacoboni, et al.
Pubblicazione: (2024)

Folate receptor beta targeting of tumor‐associated macrophages improves lymphoma cell responses to CD19 CAR T cells
di: Kerttu Kalander, et al.
Pubblicazione: (2026)

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia
di: Bela Patel, et al.
Pubblicazione: (2024)

Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials
di: Celia González‐Gil, et al.
Pubblicazione: (2025)

TWIST2 high expression defines a novel subtype of B‐cell precursor acute lymphoblastic leukemia
di: Tao Zeng, et al.
Pubblicazione: (2026)

An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome‐like acute lymphoblastic leukemia
di: Zicong Huang, et al.
Pubblicazione: (2024)

Correction to “Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials”
Pubblicazione: (2026)

Parents' perception of treatment‐related toxicity in children treated according to the NOPHO ALL2008 protocol for acute lymphoblastic leukemia
di: Nina Mogensen, et al.
Pubblicazione: (2024)

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
di: André Baruchel, et al.
Pubblicazione: (2025)

Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
di: Núria Martínez‐Cibrián, et al.
Pubblicazione: (2025)

Absence of identifiable granulopoiesis at diagnosis of childhood acute lymphoblastic leukemia conveys an extremely high risk of early blood culture‐positive infection
di: Elli‐Maija Ukonmaanaho, et al.
Pubblicazione: (2026)

NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarker
di: Emma Kroeze, et al.
Pubblicazione: (2024)

Tet2 deficiency promotes IgG1+ B‐cell expansion and differentiation blockade through deregulation of the Nfkbia –c‐Rel axis
di: Hussein Ghamlouch, et al.
Pubblicazione: (2026)

Prospective phase II study of allogeneic hematopoietic stem cell transplantation with targeted busulfan, fludarabine, and etoposide conditioning in pediatric acute lymphoblastic leukemia
di: Kyung Taek Hong, et al.
Pubblicazione: (2024)

Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine‐induced adverse effects in an acute lymphoblastic leukemia patient‐derived xenograft model
di: Hana Starobova, et al.
Pubblicazione: (2025)

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
di: Maeve A. O'Reilly, et al.
Pubblicazione: (2024)

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
di: Niels W. C. J. van de Donk, et al.
Pubblicazione: (2025)

Improved post‐transplant outcomes since 2000 for Ph‐positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party
di: Ali Bazarbachi, et al.
Pubblicazione: (2025)

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
di: Jean Galtier, et al.
Pubblicazione: (2025)

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
di: Riccardo Bomben, et al.
Pubblicazione: (2024)